Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Titel:
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Auteur:
Zhong, Wen-Zhao Wang, Qun Mao, Wei-Min Xu, Song-Tao Wu, Lin Shen, Yi Liu, Yong-Yu Chen, Chun Cheng, Ying Xu, Lin Wang, Jun Fei, Ke Li, Xiao-Fei Li, Jian Huang, Cheng Liu, Zhi-Dong Xu, Shun Chen, Ke-Neng Xu, Shi-Dong Liu, Lun-Xu Yu, Ping Wang, Bu-Hai Ma, Hai-Tao Yan, Hong-Hong Yang, Xue-Ning Zhou, Qing Wu, Yi-Long